Zach Levine supports clients in market access, product commercialization, and reimbursement strategy.

He applies his background in qualitative research and health policy to help clients understand the evolving U.S. health market and optimize product access and delivery.

Prior to joining Avalere, Zach worked at ASRC Federal as a contractor for the Centers for Medicare and Medicaid Services (CMS), where he supported CMS’ Office of Information Technology. Before that, he held positions as a research assistant with the Vaccine Confidence Project, London School of Hygiene and Tropical Medicine, and as a legal intern with the Camden Coalition ACO in New Jersey.

Zach has an AB in anthropology from Princeton University with a Certificate in Global Health and Health Policy.

Authored Content

The ESRD Treatment Choice model demonstrates an increased focus on improving health outcomes for Medicare patients receiving dialysis by realigning incentives to favor the adoption of home dialysis and increasing the rate at which patients receive kidney transplants. This mandatory model could lead to significant disruption for stakeholders in the coming years. Understanding the risk and opportunities associated with this model will be critical for patients, providers, and manufacturers alike.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from Avalere’s Market Access continue their discussion on clinical pathways in oncology, exploring how they are developed and what cancers and treatment modalities are included.

On August 25, “Calcimimetic Use in Dialysis-Dependent Medicare Fee-for-Service Beneficiaries and Implications for Bundled Payment” was published in Kidney 360. The article featured research and analytics conducted by Avalere experts.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from Avalere’s Market Access practice discuss clinical pathways as they relate to value in oncology.

As treatment advancements in oncology continue, stakeholders are modifying their approaches to defining value and managing care

The kidney care payment and delivery landscape was poised for change in 2020 due to existing policies and market trends. Given the specific risk COVID-19 poses to these patients, the pandemic is creating new challenges and potentially accelerating existing trends in the kidney care space.

Tune in to hear the final episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 3, we’ll be focusing on the End Stage Renal Disease (ESRD) Prospective Payment System, with a focus on proposed payment changes for innovative drugs, supplies, and equipment and updates to the Quality Incentive Program (QIP).

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.